摘要
对于接受标准一线治疗达到疾病控制的转移性结直肠癌(mCRC),后续治疗策略的制订应在维持疗效的同时注重改善患者生活质量。化疗联合抗表皮生长因子受体(EGFR)单抗是RAS野生型mCRC患者的标准一线治疗方案。当一线含抗EGFR单抗诱导治疗达到最佳疗效、且处于疾病缓解或稳定状态时,含抗EGFR单抗维持治疗方案可在维持疗效获益的同时,降低毒副反应和提高患者生活质量。本共识基于循证医学和临床实践,进一步明确抗EGFR单抗维持治疗的应用时机、方案选择、不良反应管理和后续策略选择,为抗EGFR单抗维持治疗提供临床应用规范化标准和指导,以期使患者的治疗最大化获益。
For patients with metastatic colorectal cancer(mCRC)who achieve disease control during first-line standard therapy,post-induction strategies should emphasize on quality of life improvement while maintaining disease control.Chemotherapy combined with anti-epidermal growth factor receptor(EGFR)monoclonal antibody is the standard first-line treatment for RAS wild-type mCRC patients.After anti-EGFR-based first-line induction therapy achieves at least stable disease,anti-EGFR-based maintenance treatment could maintain disease control while keeping a good safety profile.Based on research evidence and clinical practice,the Chinese expert consensus on anti-EGFR-based maintenance strategy for RAS wild-type mCRC aims to futher clarify the treatment timing,regimen options,adverse reaction management and follow-up strategy,providing standardized guidance to maximize the clinical benefit in RAS wild-type mCRC.
出处
《中华胃肠外科杂志》
CSCD
北大核心
2024年第4期316-325,共10页
Chinese Journal of Gastrointestinal Surgery
关键词
结直肠肿瘤
转移性
RAS野生型
抗EGFR单抗
维持治疗
Colorectal neoplasms,metastatic
RAS wild type
Anti-EGFR monoclonal antibody
Maintenance therapy
